Hypofractionation (fewer, larger radiotherapy doses)
Giving radiotherapy in fewer, bigger daily doses (fractions) so a course takes one to three weeks instead of five to seven, with equal cure and side effects for many cancers. Convenience, cost and machine capacity all improve.
Normal tissue tolerates radiation better when it is split into daily fractions, historically 1.8-2 Gy over 5-7 weeks. Randomised trials showed moderate hypofractionation (2.7-3 Gy, 15-20 fractions) is equivalent in breast (START, whole-breast 40 Gy/15) and prostate (CHHiP, PROFIT), and ultra-hypofractionation (5 fractions: FAST-Forward for breast 26 Gy/5, PACE-B for prostate) also holds up. Single 8 Gy fractions suffice for bone pain. SBRT takes the principle to its extreme. Short-course (5 × 5 Gy) rectal radiotherapy is part of total neoadjuvant therapy. Adoption lags in some health systems that are paid per fraction.
Pages like this
not linked directly; found by shared links- TermRe-irradiation
Shares Brachytherapy (internal radiotherapy), Gray unit (Gy), Stereotactic body radiotherapy (SBRT / SABR), Colorectal cancer.
- TermTotal mesorectal excision (TME)
Shares Total neoadjuvant therapy (TNT, rectal cancer), Colorectal cancer.
- TechnologyBone-modifying agents (bisphosphonates, denosumab)
Shares Bone metastases and skeletal-related events, Prostate cancer, HR-positive / HER2-negative breast cancer.
- TechnologyPalliative radiotherapy
Shares Bone metastases and skeletal-related events, Prostate cancer, HR-positive / HER2-negative breast cancer.
- TermMastectomy
Shares Lumpectomy (breast-conserving surgery), HR-positive / HER2-negative breast cancer.
- TermDuctal carcinoma in situ (DCIS)
Shares Lumpectomy (breast-conserving surgery), HR-positive / HER2-negative breast cancer.
- TermChemoradiation (chemoradiotherapy, CRT)
Shares Total neoadjuvant therapy (TNT, rectal cancer), IMRT / IGRT / VMAT (modern external beam radiotherapy).
- TermFOLFOX, FOLFIRI, FOLFIRINOX and CAPOX
Shares Total neoadjuvant therapy (TNT, rectal cancer), Colorectal cancer.